Rankings
▼
Calendar
DNLI Q1 2024 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
-100.0% YoY
Gross Profit
$0
Operating Income
-$118M
Net Income
-$102M
EPS (Diluted)
$-0.68
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$114M
Free Cash Flow
-$116M
Stock-Based Comp.
$28M
Balance Sheet
Total Assets
$1.6B
Total Liabilities
$126M
Stockholders' Equity
$1.5B
Cash & Equivalents
$61M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$35M
-100.0%
Gross Profit
$0
$35M
-100.0%
Operating Income
-$118M
-$121M
+2.6%
Net Income
-$102M
-$110M
+7.3%
← FY 2024
All Quarters
Q2 2024 →